PD-1-positive B-cell Peptide Antigen/MVF IMU-201/Montanide Vaccine

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** A cancer vaccine consisting of the fusion peptide IMU-201, composed of the B-cell epitope APi2568 (amino acids 92-110) derived from the extracellular domain (ECD) of the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), linked to a promiscuous T-cell epitope derived from measles virus fusion protein (MVF; amino acid residues 288-302) via a 4-amino acid linker (Gly-Pro-Ser-Leu), and combined with the immunoadjuvant Montanide ISA 720, with potential immunostimulatory, immune checkpoint inhibitory and antineoplastic activities. Upon administration, IMU-201/montanide vaccine induces the production of polyclonal antibodies against PD-1. In turn, the antibodies bind to PD-1, and inhibit PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.

**Synonyms:** - IMU-201/Montanide Vaccine - PD-1-positive B-cell Peptide Antigen/Measles Virus Fusion Protein IMU-201/Montanide Vaccine - PD1-Vaxx